TREATMENT COMPLETION RATES in multi-drug-resistant tuberculosis (MDR-TB) are poor. Only half of patients with MDR-TB are successfully treated.[@i1027-3719-22-8-926-b1] Treatment default, reported to be as high as 40% in some settings, is a significant contributor to poor treatment outcomes.[@i1027-3719-22-8-926-b2] The drugs used to treat MDR-TB have significant adverse effects, which have been described in one qualitative study to be worse than the disease itself,[@i1027-3719-22-8-926-b5] and may result in poor treatment adherence or loss to follow-up.[@i1027-3719-22-8-926-b6]

Kanamycin (KM) is a key second-line drug in the intensive phase of treatment for MDR-TB, but has considerable toxicity, including irreversible deafness and renal impairment.[@i1027-3719-22-8-926-b7] The pain associated with the intramuscular administration of KM is also significant and, with repeated dosing, a painful induration may develop at the injection site.[@i1027-3719-22-8-926-b5]Lidocaine is a local anaesthetic which significantly reduces the pain immediately following the intramuscular injection of some drugs,[@i1027-3719-22-8-926-b10],[@i1027-3719-22-8-926-b11] but it is currently unknown whether lidocaine has a similar effect in adult patients treated with KM for MDR-TB. Addressing the pain associated with KM administration could enhance the tolerability of MDR-TB treatment regimens and improve long-term outcomes.

STUDY POPULATION AND METHODS
============================

We performed a randomised single-blinded crossover study to compare injection-site pain from intramuscular KM with and without lidocaine. We recruited patients who were aged ⩾18 years between July 2016 and April 2017 on standard treatment for MDR-TB at Brooklyn Chest Hospital and D P Marais Hospital in Cape Town, South Africa.

During the study period, the treatment regimen for MDR-TB comprised pyrazinamide, moxifloxacin, KM, terizidone, and either ethionamide or isoniazid depending on the results of the line-probe assay for *kat*G and *inh*A Mycobacterium tuberculosis mutations identified in pretreatment sputum cultures, which would indicate high-level resistance to isoniazid or ethionamide, respectively.[@i1027-3719-22-8-926-b12] Ethambutol (EMB) was added if a patient had no exposure to EMB in the month before treatment initiation and suspicion for EMB resistance was low.[@i1027-3719-22-8-926-b13] Randomisation was performed manually by an appointed administrator who was not involved in the study design or implementation. Twenty cards, half of which were labelled 'lidocaine' and other half labelled 'no lidocaine', were placed in separate sealed opaque envelopes before randomisation. Immediately before each participant\'s first pain assessment, a new envelope was opened revealing whether KM was to be administered alone or mixed with lidocaine. The envelopes were opened sequentially starting with envelope no. 1 for the first participant. As some participants were unable to complete the study and recruitment therefore continued beyond the initial recruitment target, six additional envelopes were prepared in an identical manner. The KM dose was adjusted for creatinine clearance at the discretion of the treating clinician and the same dose was administered on both pain assessment occasions. The Wong-Baker FACES^®^ pain rating scale (Wong-Baker FACES Foundation, Oklahoma City, OK, USA) was used to assess the pain caused by the KM injection on two separate occasions approximately 7--14 days apart.[@i1027-3719-22-8-926-b14] The Wong-Baker Faces pain rating scale is a validated pain assessment tool designed to assist health care providers measure pain using patient self-assessment. The scale is numbered 0 to 10 and is accompanied by a 'grimace scale' of faces to assist patients with the interpretation of pain, whereby the facial grimace increases with higher reported pain scores. We assessed pain at the following time points post-dose: immediately after the injection as well as at 15 min, 30 min, 60 min, 2 h, 6 h and 10 h. Participants were blinded to the addition of lidocaine and to the results of their previous pain assessments to avoid influence from earlier pain scores.

One ml of 2% lidocaine was mixed with a 3 ml ampule of KM to create 4 ml of solution volume. Depending on the prescribed dose of KM, either 2 ml of the solution (500 mg), 3 ml of solution (750 mg) or the entire 4 ml of the solution (1 g) were administered intramuscularly into the superior-lateral quadrant of the buttock using a 22-gauge needle on the opposite side to that used the previous day to prevent the influence of residual pain from the previous dose. If lidocaine was not administered together with KM, participants received either a 3 ml (1 g), 2.25 ml (750 mg) or 1.5 ml (500 mg) KM injection. Blood was drawn on both occasions pre-dose as well as at 2, 4, 6, 8 and 10 h post-dose to assess the effect of lidocaine on KM pharmacokinetics. We used the K10 Anxiety and Depression Scale to screen for psychological distress, which we considered to be a possible influence on participant pain thresholds.[@i1027-3719-22-8-926-b15] The K10 Anxiety and Depression Scale was specifically designed to identify psychological distress in the previous month using 10 questions. The answers to the questions are scored 1--5, with higher scores recorded with increasing symptom frequency. Patients who score under 20 are likely to be well, with higher scores associated with increasing severity of mental disorders.[@i1027-3719-22-8-926-b16]

Plasma concentrations of KM A were determined using liquid chromatography-tandem mass spectrometry validated according to US Food and Drug Administration and European Medicines Agency guidelines.[@i1027-3719-22-8-926-b17],[@i1027-3719-22-8-926-b18] Samples were processed with a solid-phase extraction method using 50 μl of plasma. The extracted sample (5 μl) was injected onto the high-performance liquid chromatography column. Isocratic chromatographic separation was achieved on a Discovery C18 analytical column (5 6 μm, 50 mm 3 4.6 mm) using 4 mM heptafluorobutyric acid in 0.1% formic acid in water/acetonitrile (80:20, *v/v*) at a flow-rate of 500 μl/min. The mobile phase flow was split (1:1) at the source of the mass spectrometer. An AB Sciex API 3000 mass spectrometer (Applied Biosystems, Foster City, CA, USA) was operated at unit resolution in multiple-reaction monitoring mode to monitor transition of the protonated molecular ions at *m/z* 485.2 to the product ions at *m/z* 163.2 for KM A and the protonated molecular ions at *m/z* 494.3 to the product ions at *m/z* 165.3 for the KM-d9 internal standard. Electrospray ionisation was used for ion production. The assay was validated over the concentration range 0.625--40 μg/ml. The combined accuracy (%Nom) and precision (%CV) statistics of the limit of quantification, low, medium and high-quality controls (three validation batches, *n* = 18) were respectively 101.3--107.0%, and 3.0--14.3%.

Sample size
-----------

Using the report by Park et al. describing KM pharmacokinetics,[@i1027-3719-22-8-926-b19] and assuming that data would be non-parametric, we estimated that a minimum of 16 patients would be required to detect a 20% change in pharmacokinetics between the two groups. Considering the paucity of data on KM pharmacokinetics, we considered a target sample size of 20 participants would be sufficient to allow for any inaccuracy in power estimation.

Statistics
----------

We used Stata v15.0 (Stata Corp, College Station, TX, USA) to compare pain scores using the Wilcoxon signed-rank test with and without lidocaine at each time point, as well as non-compartmental KM pharmacokinetics with and without lidocaine. We determined the following pharmacokinetic parameters: area under the concentration--time curve at 0--10 h (AUC~0--10~), AUC to infinity (AUC~∞~), half-life, peak concentration (C~max~) and time to C~max~. We used the trapezoidal rule to calculate AUC~0--10~ and extrapolation of the exponential decline to calculate AUC~∞~. In a secondary analysis, we used multilevel ordered logistic regression to identify the factors associated with participant pain scores, including participants who completed the study and those who completed only one pain assessment. We identified the following variables a priori, which we analysed with single regression analyses: the use of lidocaine, time of pain assessment post-dose, human immunodeficiency virus (HIV) status, KM dose in mg/kg, volume of solution injected, sequence of randomisation, body mass index, sex, age and presence of psychological distress, defined as a score of ⩾20 using the K10 screening tool.[@i1027-3719-22-8-926-b16] We included variables with *P* \< 0.2 in the multiple regression analysis.

Ethics
------

The study protocol was approved by the University of Cape Town Human Research Ethics Committee, Cape Town (HREC 105/2016). Informed consent was provided by each participant in their language of choice (English, Afrikaans or Xhosa).

RESULTS
=======

We recruited 29 participants, 20 of whom finished the study, and five completed pain assessments on only one occasion. Characteristics at each dosing occasion of the 20 participants who completed the study are given in [Table 1](#i1027-3719-22-8-926-t01){ref-type="table"}. Twelve participants received 750 mg, five participants received 1000 mg and three participants were dosed with 500 mg of KM. One participant had a reduced creatinine clearance of 30.2 ml/min on the first and 34.3 ml/min on the second dosing occasion.

###### 

Participant characteristics of 20 patients on treatment for MDR-TB in a single-blinded randomised crossover pharmacokinetic analysis of kanamycin with and without lidocaine

![](i1027-3719-22-8-926-t01)

Pharmacokinetic parameters and drug concentrations of KM dosed with and without lidocaine are shown in [Table 2](#i1027-3719-22-8-926-t02){ref-type="table"}; 19 participants were included as the KM concentrations for one participant were not available at the time of data analyses. The [Figure](#i1027-3719-22-8-926-f01){ref-type="fig"} shows the pain scores following KM administration with and without lidocaine at each evaluated time point post-dose. Lidocaine dosed with KM reduced the pain scores reported by participants significantly immediately following the injection (*P* = 0.02) and at 15 min after dosing (*P* = 0.02). On multilevel ordered logistic regression analyses ([Table 3](#i1027-3719-22-8-926-t03){ref-type="table"}), two factors were negatively associated with differences in participant pain scores at each dosing occasion: use of lidocaine and time post-dose. HIV infection had a positive association with pain scores. We found symptoms of psychological distress, including depression, in three participants, but there was no association of psychological distress with pain.

###### 

Pharmacokinetic parameters of kanamycin at steady state with and without lidocaine in a crossover study of patients on treatment for multidrug-resistant tuberculosis
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![Median pain scores with and without lidocaine at each time point following the intramuscular administration of kanamycin in 20 participants treated for multidrug-resistant tuberculosis. ^X^ P = 0.02. Box midlines = median values; upper and lower bounds of boxes = interquartile range; upper and lower bounds of whiskers = 1.5 × the interquartile range.](i1027-3719-22-8-926-f01){#i1027-3719-22-8-926-f01}

###### 

Multilevel ordered logistic regression analysis of the factors associated with injection-site pain from intramuscular administration of kanamycin with and without lidocaine in participants on treatment for multidrug-resistant tuberculosis
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DISCUSSION
==========

Our finding that lidocaine co-administered with KM reduces injection-site pain in patients treated for MDR-TB could potentially improve the tolerability of MDR-TB treatment. KM is currently considered a key component of treatment regimens for MDR-TB by the World Health Organization.[@i1027-3719-22-8-926-b20] The toxicity and poor tolerability of the drugs used to treat MDR-TB are widely accepted to be significant factors affecting adherence and retention in care, resulting in poor treatment outcomes.[@i1027-3719-22-8-926-b6] Reducing the pain associated with the intramuscular injection of KM, which is often not included in reports describing adverse effects in patients treated for MDR-TB, is an important step towards improving the tolerability of the intensive phase of MDR-TB treatment.

We found that use of lidocaine significantly lowered pain scores in the first 15 min following KM injection, which is important considering that the highest pain scores were reported by participants immediately post-dose, and that the median time to resolution of pain was 30 min. Lidocaine has a rapid onset of action and a limited toxicity profile unless administered intravenously.[@i1027-3719-22-8-926-b21],[@i1027-3719-22-8-926-b22] Furthermore, lidocaine is inexpensive and widely available and therefore appropriate for use in low- and middle-income settings, which have the highest burden of MDR-TB.

Data on KM pharmacokinetics are limited. We found that the C~max~ and AUC of KM were in accordance with the expected range.[@i1027-3719-22-8-926-b19],[@i1027-3719-22-8-926-b23] A higher C~max~ was found in a small study of patients treated for MDR-TB in Korea with a higher dose of KM.[@i1027-3719-22-8-926-b24] Lidocaine had no effect on KM pharmacokinetics; this finding is in line with the findings of others who have assessed the effect of lidocaine on the pharmacokinetics of other drugs when administered intra-muscularly.[@i1027-3719-22-8-926-b10]

In the regression analysis, we found use of lidocaine to be independently associated with pain reduction in the single and multiple variable model. As participants received a higher volume of solution when dosed with lidocaine, we explored the possibility in the regression model that a higher volume of injected solution may increase pain due to a greater stretch on pain receptors, but found this to be non-significant. We found HIV infection to be associated with a higher pain score, although this finding needs to be interpreted with caution as the confidence intervals were wide, likely due to the small sample size. HIV infection has been associated with increased morbidity, including depression, which has been shown in several studies to lower pain thresholds.[@i1027-3719-22-8-926-b25],[@i1027-3719-22-8-926-b26] We observed symptoms of psychological distress, including anxiety and depression, in three participants who were HIV-infected, although the presence of these symptoms was not associated with higher pain scores in the regression analysis. However, our study was not powered to assess the influence of mental health or HIV infection on pain scores.

Our study had three main limitations. First, for logistical reasons only the participants were blinded to whether KM was dosed with lidocaine or not. However, single blinding was very unlikely to cause bias as the participants completed the pain scores without input from study staff. Second, pain assessments were done on occasion 1 and occasion 2 after a median of approximately 6 and 8 weeks of treatment, respectively. As repeated administration of KM may result in a painful induration at the injection site, we cannot exclude the possibility that pain scores may have been different if pain assessments had been conducted sooner or later after treatment initiation. Third, study participants were all in-patients with a high prevalence of comorbidities and psychosocial problems. The results may therefore not be generalisable to all MDR-TB patients.

CONCLUSION
==========

Lidocaine use reduces the pain associated with KM injections. Given the toxicity and poor tolerability of the MDR-TB treatment regimen, reducing the pain caused by the injectable during the intensive phase of treatment could potentially result in improving adherence and, ultimately, treatment completion rates in MDR-TB.
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